BioSig Technologies Confirms Full Compliance with Nasdaq Requirements for Continued Listing on The Nasdaq Capital Market March 26, 2025
BioSig Technologies’ Common Stock to Resume Trading on the NASDAQ Exchange, Wednesday, October 23, 2024 After Its Successful Appeal to the NASDAQ Panel October 22, 2024
BioSig Technologies Announces Intent to Acquire the Assets of Neuro-Kinesis Corporation July 31, 2024
BioSig Technologies Improves Balance Sheet, Announces Reduction in Outstanding Payables during Q2 2024 July 25, 2024
BioSig Technologies Appoints Mr. Ferdinand Groenewald to Position of Interim Chief Financial Officer and Principal Accounting Officer June 10, 2024
BioSig Announces Closing of $3 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules May 30, 2024
BioSig Announces $3 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules May 30, 2024
BioSig Technologies Chief Executive Officer Mr. Anthony Amato Issues the Following Letter to Shareholders May 21, 2024
BioSig Technologies, Inc. Announces New Appointments to its Now Fully Constituted Board of Directors, which is Comprised of 5 Board Members, 3 Independent May 3, 2024
